Uganda: Ambassador Zhang Lizhong introduced China's Position on the United States (US) "Reciprocal Tariffs" at International Chinese Language Day Event
On April 17, Ambassador Zhang Lizhong elaborated on China's position against the "Reciprocal Tariffs" by the US, at the 2025 International Chinese Language Day celebration hosted by the Confucius Institute at Makerere University.
Ambassador Zhang reiterated that the US had adopted unilateralism, protectionism, bullying and hegemony through the forced tariffs upon its trade partners. The wonton practice has deeply violated the justified rights and people's welfare worldwide, destabilized global economical orders, and disturbed free trade, which China firmly opposed. China does not make trouble, but has no fear of trouble. China has adopted consolidated counter measures to protect her own legitimate rights, safeguard international justice and free trade. China stays committed to working with Global South with Uganda included, to practice true multilateralism, oppose unilateral coercive measures and economic bullying, so as to foster an open world economy.
Professor Wamala appreciated China's position, while he encouraged Ugandan students to learn Chinese and devote themselves to deepening China-Uganda friendship. Distributed by APO Group on behalf of Embassy of the People's Republic of China in the Republic of Uganda.
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an 'as is' and 'as available' basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
2 hours ago
- Web Release
Central Pattana & Partners Invest THB 1B in ‘Summer Grand Sale 2025' to Boost Tourism and Thailand's Shopping Appeal
Central Pattana plc, Thailand's leading real estate developer and operator of Central shopping centers nationwide, is teaming up with affiliates under Central Group and key partners across both public and private sectors to launch the Summer Grand Sale 2025—the biggest mid-year sale shopping event of the year. With an investment of THB 1 billion, the campaign offers discounts of up to 80% from over 28,000 brands and 12,000 stores across Central shopping centers. It targets a global audience, including short-haul, long-haul, and high-spending international shoppers. The event will run from 30 May to 13 July 2025 at premier locations including centralwOrld, Central Village Outlet, Central Pattaya, Central Marina Outlet, Central Samui, and Central Phuket. This landmark campaign is backed by Thailand's largest retail alliance, including Central Retail, Central Pattana shopping centers, Central Department Store, Robinson Department Store, Central Online (Central App), Supersports, Central Marketing Group (CMG), Tops Food Hall, Tops, Tops Care, GO Wholesale, Power Buy, OfficeMate, B2S, Robinson Lifestyle, Central Restaurants Group, Centara Hotels and Resorts, GO Hotel, Jubilee Diamond, Evolt Technology, Major Cineplex, SF Cinema, and The 1. It is also supported by the Tourism Authority of Thailand and other strategic partners. Central Pattana continues to collaborate closely with the Tourism Authority of Thailand under the Amazing Thailand Grand Sale campaign to establish Thailand as a premier global shopping destination. This campaign aims to highlight Thailand as a destination rich in food, culture, and shopping experiences. The campaign strategically targets quality tourists, including travelers from Middle East, China, Singapore, Hong Kong, Taiwan, and Malaysia, as well as long-haul visitors from Russia, Europe, the US, and Central Asia. Insights reveal diverse shopper preferences: Chinese tourists often seek Thai fashion and popular eateries; Hong Kong and Singaporean travelers gravitate toward craft goods and Thai desserts; Europeans and Americans favor international fashion brands and premium restaurants, while Middle Eastern and Russian tourists are especially drawn to luxury goods. Central Pattana continues to attract high-spending tourists— 'Quality Shoppers'—as demonstrated by growing e-wallet spending in key tourist malls such as Central Phuket, Central Chiangmai, Central Pattaya, and centralwOrld. This sustained growth reflects the success of its strategic efforts to drive premium tourism. Exclusive Offers for International Visitors: During Summer Grand Sale 2025, international tourists can enjoy exclusive promotions by signing up for The 1 Tourist membership. Members receive a free Tourist Welcome Package with discounts of up to 40%* at participating brands across all Central shopping centers in Thailand. Shoppers who spend THB 6,000* (or THB 5,000* for Klook customers) will receive a complimentary Good Goods Tote Bag valued at THB 690. Offers are available from 30 May to 13 July 2025 at the participating Central locations listed above.
Zawya
2 hours ago
- Zawya
US, China reach deal to ease export curbs, keep tariff truce alive
LONDON - U.S. and Chinese officials said on Tuesday they had agreed on a framework to get their trade truce back on track and remove China's export restrictions on rare earths while offering little sign of a durable resolution to longstanding trade tensions. At the end of two days of intense negotiations in London, U.S. Commerce Secretary Howard Lutnick told reporters the framework deal puts "meat on the bones" of an agreement reached last month in Geneva to ease bilateral retaliatory tariffs that had reached crushing triple-digit levels. But the Geneva deal had faltered over China's continued curbs on critical minerals exports, prompting the Trump administration to respond with export controls of its own preventing shipments of semiconductor design software, aircraft and other goods to China. Lutnick said the agreement reached in London would remove restrictions on Chinese exports of rare earth minerals and magnets and some of the recent U.S. export restrictions "in a balanced way", but did not provide details after the talks concluded around midnight London time (2300 GMT). "We have reached a framework to implement the Geneva consensus and the call between the two presidents," Lutnick said, adding that both sides will now return to present the framework to their respective presidents for approvals. "And if that is approved, we will then implement the framework," he said. In a separate briefing, China's Vice Commerce Minister Li Chenggang also said a trade framework had been reached in principle that would be taken back to U.S. and Chinese leaders. U.S. President Donald Trump's shifting tariff policies have roiled global markets, sparked congestion and confusion in major ports, and cost companies tens of billions of dollars in lost sales and higher costs. The World Bank on Tuesday slashed its global growth forecast for 2025 by four-tenths of a percentage point to 2.3%, saying higher tariffs and heightened uncertainty posed a "significant headwind" for nearly all economies. The deal may keep the Geneva agreement from unravelling over duelling export controls, but does little to resolve deep differences over Trump's unilateral tariffs and longstanding U.S. complaints about China's state-led, export-driven economic model. The two sides left Geneva with fundamentally different views of the terms of that agreement and needed to be more specific on required actions, said Josh Lipsky, senior director of the Atlantic Council's GeoEconomics Center in Washington. "They are back to square one but that's much better than square zero," Lipsky added. The two sides have until August 10 to negotiate a more comprehensive agreement to ease trade tensions, or tariff rates will snap back from about 30% to 145% on the U.S. side and from 10% to 125% on the Chinese side. MARKETS CAUTIOUS Global stocks have recovered their hefty losses after Trump's April "Liberation Day" tariff announcement and are now near record highs. Investors burned by earlier turmoil offered a cautious response to the deal and MSCI's broadest index of Asia-Pacific shares outside Japan rose 0.57%. "The devil will be in the details, but the lack of reaction suggests this outcome was fully expected," said Chris Weston, head of research at Pepperstone in Melbourne. "The details matter, especially around the degree of rare earths bound for the U.S., and the subsequent freedom for U.S.-produced chips to head east, but for now as long as the headlines of talks between the two parties remain constructive, risk assets should remain supported." Signs of the curbs loosening surfaced in China, as several Shenzhen-listed rare earth magnet firms, including JL MAG Rare-Earth Innuovo Technology and Beijing Zhong Ke San Huan said they have obtained export licenses from Chinese authorities. China holds a near-monopoly on rare earth magnets, a crucial component in electric vehicle motors, and its decision in April to suspend exports of a wide range of critical minerals and magnets upended global supply chains. In May, the U.S. responded by halting shipments of semiconductor design software and chemicals and aviation equipment, revoking export licences that had been previously issued. CHINA EXPORTS PLUNGED A resolution to the trade war may require policy adjustments from all countries to treat financial imbalances or otherwise greatly risk mutual economic damage, European Central Bank President Christine Lagarde said on a rare visit to Beijing on Wednesday. Customs data published on Monday showed that China's overall exports to the U.S. plunged 34.5% in May, the sharpest drop since the outbreak of the COVID pandemic. While the impact on U.S. inflation and its jobs market has so far been muted, tariffs have hammered U.S. business and household confidence and the dollar remains under pressure. Beijing-based lawyer Peter Wu, 28, saw the talks as "a good signal" even if details were not fully negotiated. "I feel that fighting a trade war in the context of global integration is a lose-lose situation for both sides. I naturally hope that my motherland will be better," he said. China, Mexico, the European Union, Japan, Canada and many airlines and aerospace companies worldwide urged the Trump administration not to impose new national security tariffs on imported commercial planes and parts, according to documents released Tuesday. Just after the framework deal was announced, a U.S. appeals court allowed Trump's most sweeping tariffs to stay in effect while it reviews a lower court decision blocking them on grounds that they exceeded Trump's legal authority by imposing them. The decision keeps alive a key pressure point on China, Trump's currently suspended 34% "reciprocal" duties that had prompted swift tariff escalation. (Additional reporting by David Milliken and William James in London and Sachin Ravikumar; Ethan Wang, Shi Bu, Yuhan Lin and Alessandro Diviggiano in Beijing; Writing by David Lawder, Kate Holton and Liz Lee; Editing by David Evans, Mark Potter, Nick Zieminski and Lincoln Feast.)
Arabian Post
3 hours ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
